BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 29971626)

  • 21. Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada.
    Blanchette PS; Lam M; Richard L; Allen B; Shariff SZ; Vandenberg T; Pritchard KI; Chan KKW; Louie AV; Desautels D; Raphael J; Earle CC
    Breast Cancer Res Treat; 2020 Jan; 179(1):217-227. PubMed ID: 31571072
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer.
    Wassermann J; Gelber SI; Rosenberg SM; Ruddy KJ; Tamimi RM; Schapira L; Borges VF; Come SE; Meyer ME; Partridge AH
    Cancer; 2019 Sep; 125(18):3266-3274. PubMed ID: 31120571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
    Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
    Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physical activity, health-related quality of life, and adjuvant endocrine therapy-related symptoms in women with hormone receptor-positive breast cancer.
    Sheppard VB; Dash C; Nomura S; Sutton AL; Franco RL; Lucas A; Ross M; Adams-Campbell L
    Cancer; 2020 Sep; 126(17):4059-4066. PubMed ID: 32614992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Racial differences in receipt of adjuvant hormonal therapy among Medicaid enrollees in South Carolina diagnosed with breast cancer.
    Felder TM; Do DP; Lu ZK; Lal LS; Heiney SP; Bennett CL
    Breast Cancer Res Treat; 2016 May; 157(1):193-200. PubMed ID: 27120468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management.
    Cavazza M; Banks H; Ercolanoni M; Cukaj G; Bianchi G; Capri G; Longo F
    Breast Cancer Res Treat; 2020 Aug; 183(1):189-199. PubMed ID: 32591986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adherence to Adjuvant Endocrine Therapy in Christchurch Women with Early Breast Cancer.
    Robinson B; Dijkstra B; Davey V; Tomlinson S; Frampton C
    Clin Oncol (R Coll Radiol); 2018 Jan; 30(1):e9-e15. PubMed ID: 29103853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cognitive function after the initiation of adjuvant endocrine therapy in early-stage breast cancer: an observational cohort study.
    Ganz PA; Petersen L; Castellon SA; Bower JE; Silverman DH; Cole SW; Irwin MR; Belin TR
    J Clin Oncol; 2014 Nov; 32(31):3559-67. PubMed ID: 25267747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of preexisting mental illness on breast cancer endocrine therapy adherence.
    Haskins CB; McDowell BD; Carnahan RM; Fiedorowicz JG; Wallace RB; Smith BJ; Chrischilles EA
    Breast Cancer Res Treat; 2019 Feb; 174(1):197-208. PubMed ID: 30465157
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adherence to adjuvant endocrine therapy: is it a factor for ethnic differences in breast cancer outcomes in New Zealand?
    Seneviratne S; Campbell I; Scott N; Kuper-Hommel M; Kim B; Pillai A; Lawrenson R
    Breast; 2015 Feb; 24(1):62-7. PubMed ID: 25486877
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adherence to adjuvant endocrine therapy in postmenopausal breast cancer patients: A 5-year prospective study.
    Hagen KB; Aas T; Kvaløy JT; Søiland H; Lind R
    Breast; 2019 Apr; 44():52-58. PubMed ID: 30641300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endocrine therapy initiation among Medicaid-insured breast cancer survivors with hormone receptor-positive tumors.
    Wheeler SB; Kohler RE; Reeder-Hayes KE; Goyal RK; Lich KH; Moore A; Smith TW; Melvin CL; Muss HB
    J Cancer Surviv; 2014 Dec; 8(4):603-10. PubMed ID: 24866922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study.
    Frechette D; Paquet L; Verma S; Clemons M; Wheatley-Price P; Gertler SZ; Song X; Graham N; Dent S
    Breast Cancer Res Treat; 2013 Aug; 141(1):111-7. PubMed ID: 23942873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Informing women with breast cancer about endocrine therapy: effects on knowledge and adherence.
    Heisig SR; Shedden-Mora MC; von Blanckenburg P; Schuricht F; Rief W; Albert US; Nestoriuc Y
    Psychooncology; 2015 Feb; 24(2):130-7. PubMed ID: 24953538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adherence to adjuvant endocrine therapy in women with breast cancer.
    Danilak M; Chambers CR
    J Oncol Pharm Pract; 2013 Jun; 19(2):105-10. PubMed ID: 22895656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women.
    Weaver KE; Camacho F; Hwang W; Anderson R; Kimmick G
    Am J Clin Oncol; 2013 Apr; 36(2):181-7. PubMed ID: 22314001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer.
    Aiello Bowles EJ; Boudreau DM; Chubak J; Yu O; Fujii M; Chestnut J; Buist DS
    J Oncol Pract; 2012 Nov; 8(6):e149-57. PubMed ID: 23598850
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
    Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
    J Clin Oncol; 2005 Aug; 23(22):5178-87. PubMed ID: 15998905
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study.
    Wigertz A; Ahlgren J; Holmqvist M; Fornander T; Adolfsson J; Lindman H; Bergkvist L; Lambe M
    Breast Cancer Res Treat; 2012 May; 133(1):367-73. PubMed ID: 22286315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
    Punglia RS; Burstein HJ; Winer EP; Weeks JC
    J Natl Cancer Inst; 2008 May; 100(9):642-8. PubMed ID: 18445827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.